Comparison of the effects of the selective serotonin-reuptake inhibitors fluoxetine, paroxetine, citalopram and fluvoxamine in alcohol-preferring cAA rats

被引:47
作者
Maurel, S [1 ]
De Vry, J [1 ]
Schrieber, R [1 ]
机构
[1] CNS Res, Bayer AG, D-51063 Cologne, Germany
关键词
alcoholism; animal model; cAA rats; consummatory behavior; ethanol; selective serotonin-reuptake inhibitors; serotonin (receptors);
D O I
10.1016/S0741-8329(98)00046-9
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Clinical studies indicate that selective serotonin-reuptake inhibitors (SSRIs) may decrease alcohol intake and craving in particular subgroups of alcoholics. The aim of the present study was to compare the behavioral profile of various SSRIs in alcohol-preferring cAA rats, a genetic model of alcoholism. The effects of acute IP administration of fluoxetine (doses in mg/kg 1-10), citalopram (3-30), fluvoxamine (3-30) and paroxetine (1-10) on ethanol (EtOH) intake and preference, as well as food and total fluid intake, were determined in a 12-h access, water vs. 10% v/v EtOH two-bottle choice paradigm. Each compound reduced EtOH intake [Minimal Effective Doses (MEDs) 5, 10, 30 and 1 mg/kg for fluoxetine, citalopram, fluvoxamine, and paroxetine, respectively]. The degree of selectivity, that is, the extent to which reductions in EtOH intake could be separated from reductions in food and/or total fluid intake varied across the compounds. Thus, whereas EtOH intake was more markedly affected than food intake by fluoxetine, both parameters were equally affected by citalopram, and food intake was more markedly affected than EtOH intake by fluvoxamine and paroxetine. The anti-alcohol effect also differed with respect to specificity, that is, the degree to which effects on EtOH intake coincided with effects on EtOH preference. Whereas fluoxetine showed the highest level of specificity, followed by citalopram and fluvoxamine, the effect of paroxetine was nonspecific. The observed variation in the degree of selectivity and specificity of the anti-alcohol effect of SSRIs suggests that reductions in EtOH intake are not merely a consequence of a general suppressive effect on consummatory behavior. It is hypothesized that differences between the behavioral profiles of these compounds reflect a differential involvement of 5-HT receptor subtypes. (C) 1999 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:195 / 201
页数:7
相关论文
共 46 条
[1]   ZIMELDINE - A REVIEW OF ITS EFFECTS ON ETHANOL-CONSUMPTION [J].
AMIT, Z ;
SUTHERLAND, EA ;
GILL, K ;
OGREN, SO .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 1984, 8 (01) :35-54
[2]   ANORECTIC ACTIVITIES OF SEROTONIN UPTAKE INHIBITORS - CORRELATION WITH THEIR POTENCIES AT INHIBITING SEROTONIN UPTAKE INVIVO AND H-3 MAZINDOL BINDING INVITRO [J].
ANGEL, I ;
TARANGER, MA ;
CLAUSTRE, Y ;
SCATTON, B ;
LANGER, SZ .
LIFE SCIENCES, 1988, 43 (08) :651-658
[3]   FLUVOXAMINE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC EFFICACY IN DEPRESSIVE-ILLNESS [J].
BENFIELD, P ;
WARD, A .
DRUGS, 1986, 32 (04) :313-334
[4]   5-HYDROXYINDOLEACETIC ACID IN CEREBROSPINAL-FLUID IN ALCOHOLIC PATIENTS UNDER DIFFERENT CLINICAL CONDITIONS [J].
BORG, S ;
KVANDE, H ;
LILJEBERG, P ;
MOSSBERG, D ;
VALVERIUS, P .
ALCOHOL, 1985, 2 (03) :415-418
[5]   Blockade of pre- and post-synaptic 5-HT1A receptors does not modify the effect of fluoxetine or 5-hydroxytryptophan on ethanol and food intake in rats [J].
Ciccocioppo, R ;
Panocka, I ;
Polidori, C ;
Dourish, CT ;
Massi, M .
PSYCHOPHARMACOLOGY, 1997, 134 (01) :55-63
[6]  
De Vry J., 1995, Society for Neuroscience Abstracts, V21, P1698
[7]   Effects of nimodipine and other calcium channel antagonists in alcohol-preferring AA rats [J].
DeBeun, R ;
Schneider, R ;
Klein, A ;
Lohmann, A ;
DeVry, J .
ALCOHOL, 1996, 13 (03) :263-271
[8]   The calcium channel agonist BAY k 8644 reduces ethanol intake and preference in alcohol-preferring AA rats [J].
deBeun, R ;
Schneider, R ;
Klein, A ;
Lohmann, A ;
Schreiber, R ;
DeVry, J .
PSYCHOPHARMACOLOGY, 1996, 127 (04) :302-310
[9]  
DEBEUN R, 1996, BEHAV PHARMACOL, V7, P26
[10]   Selective serotonin reuptake inhibitors - Relevance of differences in their pharmacological and clinical profiles [J].
deJonghe, F ;
Swinkels, J .
CNS DRUGS, 1997, 7 (06) :452-467